Pharmacology, Toxicology and Pharmaceutical Science
Hyperkalemia
100%
Patiromer
100%
Aldosterone
100%
Chronic Kidney Failure
100%
Angiotensin
100%
Albuminuria
100%
Renin
100%
Isotopes of Potassium
60%
Losartan
58%
Spironolactone
58%
Randomized Controlled Trial
50%
Finerenone
50%
Placebo
50%
Empagliflozin
50%
Non Insulin Dependent Diabetes Mellitus
50%
Creatinine
20%
Nitroprusside Sodium
16%
Nitric Oxide
16%
Acetylcholine
16%
Angiotensin Receptor Antagonist
12%
Dipeptidyl Carboxypeptidase Inhibitor
12%
Mineralocorticoid Antagonist
12%
Biochemical Marker
8%
Vein Occlusion
8%
Nitrite
8%
Clinical Trial
8%
Cardiovascular Disease
6%
Disease Exacerbation
6%
Diabetes Mellitus
6%
Medicine and Dentistry
Empagliflozin
50%
Maturity Onset Diabetes of the Young
50%
Placebo
50%
Patiromer
50%
Vasodilatation
25%
Type 2 Diabetes
25%
Acetylcholine
16%
Blood Pressure
16%
Vascular Resistance
16%
Sodium Nitroprusside
16%
Nitric Oxide
16%
Urinary System
8%
Systemic Vascular Resistance
8%
Brachial Artery
8%
Hemodynamic
8%
Systolic Blood Pressure
8%
Vein Occlusion Plethysmography
8%
Forearm Blood Flow
8%
Clinical Trial
8%
Patient with Type 2 Diabetes
8%
Infusion
8%
Biochemical Marker
8%
Nitrite
8%
Diastolic Blood Pressure
8%
Keyphrases
Patiromer
50%
Finerenone
50%
Diabetic CKD
50%
SGLT2 Inhibition
50%
Potassium Binders
25%
Endothelium-dependent
16%
Major Selection
8%
Spironolactone
8%
Screening Effort
8%
CKD Progression
8%
Total Peripheral Resistance
8%
Brachial Artery
8%
Blood Biochemical
8%
